These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25253666)

  • 61. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.
    Le T; Cherry JD; Chang SJ; Knoll MD; Lee ML; Barenkamp S; Bernstein D; Edelman R; Edwards KM; Greenberg D; Keitel W; Treanor J; Ward JI;
    J Infect Dis; 2004 Aug; 190(3):535-44. PubMed ID: 15243929
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy - a prospective, observational cohort study from the United Kingdom.
    Rice TF; Diavatopoulos DA; Smits GP; van Gageldonk PGM; Berbers GAM; van der Klis FR; Vamvakas G; Donaldson B; Bouqueau M; Holder B; Kampmann B
    Clin Exp Immunol; 2019 Jul; 197(1):1-10. PubMed ID: 30758857
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
    Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
    Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immune responses in infants whose mothers received Tdap vaccine during pregnancy.
    Hardy-Fairbanks AJ; Pan SJ; Decker MD; Johnson DR; Greenberg DP; Kirkland KB; Talbot EA; Bernstein HH
    Pediatr Infect Dis J; 2013 Nov; 32(11):1257-60. PubMed ID: 23799518
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of Maternal Pertussis Antibodies on the Infants' Cellular Immune Responses.
    Orije MRP; García-Fogeda I; Van Dyck W; Corbière V; Mascart F; Mahieu L; Hens N; Van Damme P; Cools N; Ogunjimi B; Maertens K; Leuridan E
    Clin Infect Dis; 2022 Aug; 75(3):442-452. PubMed ID: 34849638
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
    Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
    Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
    Bartels I; Jüngert J; Lugauer S; Stehr K; Heininger U
    Vaccine; 2001 Apr; 19(23-24):3137-45. PubMed ID: 11312009
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
    Blatter M; Friedland LR; Weston WM; Li P; Howe B
    Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
    Aquino AG; Brito MG; Doniz CE; Herrera JF; Macias M; Zambrano B; Plennevaux E; Santos-Lima E
    Vaccine; 2012 Oct; 30(45):6492-500. PubMed ID: 22863658
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tdap vaccine in pregnancy and immunogenicity of pertussis and pneumococcal vaccines in children: What is the impact of different immunization schedules?
    Febriani Y; Mansour T; Sadarangani M; Ulanova M; Amaral K; Halperin SA; De Serres G; Racine É; Brousseau N
    Vaccine; 2023 Oct; 41(45):6745-6753. PubMed ID: 37816653
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.